See more : PATRIZIA SE (P1Z.SW) Income Statement Analysis – Financial Results
Complete financial analysis of China Biotech Services Holdings Limited (8037.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of China Biotech Services Holdings Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Ajanta Pharma Limited (AJANTPHARM.BO) Income Statement Analysis – Financial Results
- UMS Holdings Limited (558.SI) Income Statement Analysis – Financial Results
- Hunter Maritime Acquisition Corp. (HUNTF) Income Statement Analysis – Financial Results
- Medistim ASA (0OCD.L) Income Statement Analysis – Financial Results
- China Sunsine Chemical Holdings Ltd. (QES.SI) Income Statement Analysis – Financial Results
China Biotech Services Holdings Limited (8037.HK)
About China Biotech Services Holdings Limited
China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong. The company operates through five segments: Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, Insurance brokerage, and Others segments. It also engages in the research, development, manufacture, sale, and distribution of health related and pharmaceutical products; trading of securities; money lending business; provision of tumor immune cell therapy, immune cell storage, and health management services; and provision of coordination of healthcare providers services. In addition, the company markets and sells health supplements, slimming pills, Chinese medicines, and beauty products; trades in pharmaceutical intermediates; and offers insurance brokerage services. Further, it provides property investment and logistic services. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017. China Biotech Services Holdings Limited was founded in 1996 and is headquartered in Causeway Bay, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 211.99M | 1.85B | 623.76M | 655.79M | 59.21M | 70.30M | 105.14M | 86.57M | 34.13M | 140.39M | 85.30M | 101.35M | 45.02M | 84.18M | 160.52M | 272.28M | 270.75M | 243.39M | 197.46M |
| Cost of Revenue | 177.66M | 750.58M | 265.74M | 316.71M | 36.84M | 42.22M | 74.93M | 56.52M | 24.50M | 87.45M | 49.43M | 55.75M | 41.12M | 43.70M | 71.64M | 111.73M | 98.04M | 97.83M | 70.11M |
| Gross Profit | 34.32M | 1.10B | 358.02M | 339.08M | 22.37M | 28.08M | 30.20M | 30.04M | 9.63M | 52.94M | 35.87M | 45.60M | 3.89M | 40.48M | 88.88M | 160.55M | 172.72M | 145.56M | 127.35M |
| Gross Profit Ratio | 16.19% | 59.46% | 57.40% | 51.71% | 37.78% | 39.95% | 28.73% | 34.71% | 28.22% | 37.71% | 42.06% | 44.99% | 8.65% | 48.09% | 55.37% | 58.97% | 63.79% | 59.81% | 64.49% |
| Research & Development | 29.04M | 27.76M | 28.68M | 29.19M | 10.68M | 0.00 | 0.00 | 0.00 | 2.40M | 4.02M | 6.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 138.34M | 241.16M | 157.08M | 132.49M | 94.11M | 78.99M | 54.68M | 55.73M | 37.68M | 49.00M | 30.83M | 24.82M | 23.49M | 33.95M | 29.89M | 32.19M | 26.79M | 26.24M | 20.86M |
| Selling & Marketing | 14.61M | 13.73M | 11.72M | 11.85M | 12.38M | 16.97M | 16.81M | 20.00M | 6.27M | 31.58M | 28.62M | 23.80M | 22.90M | 27.72M | 98.17M | 161.72M | 181.71M | 118.36M | 81.22M |
| SG&A | 128.97M | 254.88M | 168.81M | 144.34M | 106.49M | 95.95M | 71.48M | 75.72M | 43.95M | 80.58M | 59.44M | 48.62M | 46.39M | 61.67M | 128.06M | 193.91M | 208.50M | 144.59M | 102.08M |
| Other Expenses | 3.99M | -3.36M | 738.00K | -5.04M | -57.00K | 172.00K | 354.00K | 699.00K | 292.00K | 1.71M | 0.00 | 428.00K | -3.07M | -7.00M | -5.85M | 768.00K | 620.00K | 459.00K | 189.00K |
| Operating Expenses | 162.00M | 251.52M | 168.81M | 139.30M | 106.43M | 95.40M | 71.38M | 75.06M | 43.95M | 80.58M | 92.69M | 57.96M | 46.39M | 54.67M | 128.06M | 194.68M | 209.12M | 145.05M | 102.27M |
| Cost & Expenses | 339.66M | 1.00B | 434.55M | 456.01M | 143.27M | 137.62M | 146.31M | 131.58M | 68.44M | 168.03M | 142.11M | 113.71M | 87.52M | 98.37M | 199.70M | 306.40M | 307.16M | 242.88M | 172.38M |
| Interest Income | 3.74M | 153.00K | 12.00K | 21.00K | 189.00K | 20.00K | 144.00K | 326.00K | 265.00K | 208.00K | 2.89M | 67.00K | 199.00K | 108.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.31M | 3.50M | 6.54M | 6.50M | 1.69M | 3.47M | 2.19M | 2.01M | 402.00K | 4.43M | 0.00 | 2.99M | 3.25M | 1.73M | 3.39M | 1.77M | 0.00 | 2.89M | 0.00 |
| Depreciation & Amortization | 55.58M | 66.40M | 68.11M | 40.34M | 20.20M | 8.25M | 7.04M | 6.87M | 5.78M | 2.56M | 1.57M | 2.15M | 3.81M | 4.19M | 5.24M | 5.35M | 4.82M | 3.98M | 3.16M |
| EBITDA | -73.46M | 936.90M | 255.32M | 249.64M | -86.31M | -57.53M | -66.17M | -86.26M | -55.57M | -71.87M | -16.43M | -10.19M | -38.89M | -12.10M | -74.81M | -27.17M | -31.59M | 4.49M | 28.24M |
| EBITDA Ratio | -34.65% | 49.16% | 41.29% | 36.74% | -96.27% | -84.03% | -26.87% | -63.55% | -106.29% | -22.29% | -19.27% | -9.59% | -92.33% | -11.86% | -24.78% | -10.57% | -11.67% | 1.85% | 14.30% |
| Operating Income | -127.67M | 851.71M | 189.44M | 200.60M | -84.06M | -69.56M | -73.29M | -69.85M | -50.26M | -63.43M | -18.01M | -11.78M | -42.50M | -16.29M | -74.21M | -34.12M | -36.41M | 510.00K | 25.08M |
| Operating Income Ratio | -60.23% | 46.00% | 30.37% | 30.59% | -141.96% | -98.94% | -69.71% | -80.69% | -147.28% | -45.18% | -21.11% | -11.63% | -94.41% | -19.35% | -46.23% | -12.53% | -13.45% | 0.21% | 12.70% |
| Total Other Income/Expenses | -14.35M | 11.12M | -9.01M | 3.43M | -20.27M | 317.00K | -2.11M | -28.49M | -9.78M | -16.05M | -25.43M | -5.05M | -4.95M | -1.73M | -41.90M | -1.77M | 158.00K | 2.92M | -521.00K |
| Income Before Tax | -142.03M | 862.83M | 180.67M | 202.80M | -109.59M | -69.24M | -75.40M | -95.14M | -60.04M | -82.33M | -59.70M | -14.77M | -45.60M | -18.02M | -83.44M | -35.89M | -36.25M | 3.43M | 24.56M |
| Income Before Tax Ratio | -67.00% | 46.60% | 28.96% | 30.92% | -185.08% | -98.49% | -71.72% | -109.90% | -175.93% | -58.65% | -69.99% | -14.58% | -101.28% | -21.40% | -51.98% | -13.18% | -13.39% | 1.41% | 12.44% |
| Income Tax Expense | -1.32M | 157.26M | 48.10M | 35.18M | -2.11M | 189.00K | 1.13M | 479.00K | -389.00K | 613.00K | 527.20K | 86.00K | 445.00K | 47.00K | 978.00K | 1.53M | 2.08M | -2.91M | 606.00K |
| Net Income | -95.45M | 705.57M | 132.57M | 167.62M | -107.48M | -64.25M | -63.02M | -50.15M | -62.27M | -82.93M | -60.23M | -20.70M | -43.56M | -16.47M | -83.56M | -37.43M | -38.33M | 528.00K | 25.17M |
| Net Income Ratio | -45.03% | 38.11% | 21.25% | 25.56% | -181.52% | -91.39% | -59.94% | -57.93% | -182.46% | -59.07% | -70.61% | -20.42% | -96.75% | -19.56% | -52.06% | -13.75% | -14.16% | 0.22% | 12.74% |
| EPS | -0.10 | 0.73 | 0.14 | 0.17 | -0.11 | -0.07 | -0.08 | -0.07 | -0.21 | -0.97 | -2.12 | -0.84 | -1.79 | -0.96 | -6.19 | -2.78 | -3.03 | 0.05 | 1.99 |
| EPS Diluted | -0.10 | 0.73 | 0.14 | 0.17 | -0.11 | -0.07 | -0.08 | -0.07 | -0.21 | -0.97 | -2.12 | -0.84 | -1.79 | -0.96 | -6.19 | -2.78 | -3.03 | 0.05 | 1.96 |
| Weighted Avg Shares Out | 963.23M | 963.23M | 964.71M | 968.49M | 960.88M | 881.72M | 801.22M | 706.88M | 294.07M | 85.47M | 28.35M | 24.52M | 24.30M | 17.22M | 13.50M | 13.45M | 12.66M | 12.44M | 12.66M |
| Weighted Avg Shares Out (Dil) | 963.23M | 963.23M | 964.71M | 968.49M | 960.88M | 881.72M | 801.22M | 706.88M | 294.07M | 85.47M | 28.35M | 24.52M | 24.30M | 17.22M | 13.50M | 13.45M | 12.66M | 12.44M | 12.81M |
Source: https://incomestatements.info
Category: Stock Reports